Osteoarthritis(OA)is the most prevalent degenerative joint disorder,affecting hundreds of millions of people globally.Current clinical approaches are confined to providing only symptomatic relief.Research over the pas...Osteoarthritis(OA)is the most prevalent degenerative joint disorder,affecting hundreds of millions of people globally.Current clinical approaches are confined to providing only symptomatic relief.Research over the past two decades has established that OA is not merely a process of wear and tear of the articular cartilage but involves abnormal remodelling of all joint tissues.Although many new mechanisms of disease have been identified in the past several decades,the efficient and sustainable delivery of drugs targeting these mechanisms in joint tissues remains a major challenge.Nanoparticles recently emerged as favoured delivery vehicles in OA treatment,offering extended drug retention,enhanced drug targeting,and improved drug stability and solubility.In this review,we consider OA as a disease affecting the entire joint and initially explore the pathophysiology of OA across multiple joint tissues,including the articular cartilage,synovium,fat pad,bone,and meniscus.We then classify nanoparticles based on their composition and structure,such as lipids,polymers,inorganic materials,peptides/proteins,and extracellular vesicles.We summarise the recent advances in their use for treatment and diagnosis of OA.Finally,we discuss the current challenges and future directions in this field.In conclusion,nanoparticle-based nanosystems are promising carriers that advance OA treatment and diagnosis.展开更多
基金supported by National Institutes of Health,Nos.R21AR078650,R01AG067698,R01AR079875(to LQ),R01AR080820Health Research Formula Fund from the Pennsylvania Department of Health(to ZC).
文摘Osteoarthritis(OA)is the most prevalent degenerative joint disorder,affecting hundreds of millions of people globally.Current clinical approaches are confined to providing only symptomatic relief.Research over the past two decades has established that OA is not merely a process of wear and tear of the articular cartilage but involves abnormal remodelling of all joint tissues.Although many new mechanisms of disease have been identified in the past several decades,the efficient and sustainable delivery of drugs targeting these mechanisms in joint tissues remains a major challenge.Nanoparticles recently emerged as favoured delivery vehicles in OA treatment,offering extended drug retention,enhanced drug targeting,and improved drug stability and solubility.In this review,we consider OA as a disease affecting the entire joint and initially explore the pathophysiology of OA across multiple joint tissues,including the articular cartilage,synovium,fat pad,bone,and meniscus.We then classify nanoparticles based on their composition and structure,such as lipids,polymers,inorganic materials,peptides/proteins,and extracellular vesicles.We summarise the recent advances in their use for treatment and diagnosis of OA.Finally,we discuss the current challenges and future directions in this field.In conclusion,nanoparticle-based nanosystems are promising carriers that advance OA treatment and diagnosis.
